This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more in the future.

| More on:
A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A little-known small-cap stock has rocketed on Wednesday morning after coming out of a two-day trading halt.

PharmAust Limited (ASX: PAA) had requested a halt to trading of its shares before the market opened on Monday.

On Tuesday evening the company released its phase 1 study results for its monepantel drug that aims to treat motor neurone disease (MND), also known as Lou Gehrig's disease.

PharmAust reported that its product showed "a superior safety, tolerability to the leading FDA approved drug Relyvrio".

As soon as the stock was free to be traded on Wednesday, the market went into a frenzy.

The PharmAust share price surged 39.5% within the first few minutes of trading.

The $147 million business, in a matter of minutes, all of a sudden became a $205 million player on the ASX.

Adapting an existing drug for different uses

Incredibly, the small cap had already soared 375% over the last 12 months even before Wednesday's pile-on.

Monepantel is a drug that's already commercially used to treat sheep for worm infestations.

PharmAust has patents for repurposing this product with the goal of treating serious diseases in humans and cancer in dogs.

Motor neurone disease currently has no cure.

The PharmAust website explains that in mammals, monepantel is "a potent inhibitor of the mTOR pathway". 

"The mTOR pathway regulates the cellular 'cleaning process', where toxic protein is broken down into macromolecules to be reused.

"This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease."

The Perth company is led by chair Dr Roger Aston and chief executive Dr Michael Thurn.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a spectacular end to the trading week for the ASX today.

Read more »

Three people jumping cheerfully in clear sunny weather.
Share Gainers

These 3 ASX 200 stocks are shooting the lights out this week. Own any?

These ASX 200 shares have soared 11% to almost 23% this week. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Share Gainers

Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher

These shares are ending the week on a positive note. But why?

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a momentous day for ASX shares, with the index hitting another record...

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why ASX, Domain, Ora Banda, and Temple & Webster's shares are storming higher today

These shares are catching the eye with strong gains on Thursday. Let's see what is happening.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

2 ASX 300 shares rocketing 6% today

Investors love what these two stocks just reported.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wonderful Wednesday session for investors today...

Read more »